haematologica
Journal of the Ferrata Storti Foundation

Longer time from diagnosis to treatment with hypomethylating agents + venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Disease (COMMAND)

by Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Yasmin Abaza, Alok Swaroop, Eric S. Winer, Mark R. Litzow, Ehab L. Atallah, Anand Ashwin Patel and Rory M. Shallis

Received: April 20, 2025.
Accepted: July 14, 2025.

Citation: Samuel J. Yates, Julian J. Weiss, Abigail Sneider, Emily Geramita, Guru Subramanian Guru Murthy, Talha Badar, Annie Im, Chenyu Lin, Wei Cheng, Yasmin Abaza, Alok Swaroop, Eric S. Winer, Mark R. Litzow, Ehab L. Atallah, Anand Ashwin Patel and Rory M. Shallis. Longer time from diagnosis to treatment with hypomethylating agents + venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Disease (COMMAND).
Haematologica. 2025 July 24. doi: 10.3324/haematol.2025.288085 [Epub ahead of print]

Longer time from diagnosis to initiation of hypomethylating agents plus venetoclax for acute myeloid leukemia does not worsen survival: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)

Short title: TDT in AML treated with HMA + venetoclax

Samuel J. Yates[1], Julian J Weiss[2], Abigail Sneider[3], Emily Geramita[4], Guru Subramanian Guru Murthy[5], Talha Badar[6], Annie Im[4], Chenyu Lin[7], Wei Cheng[8], Yasmin Abaza[9], Alok Swaroop[9], Eric S. Winer[10], Mark R. Litzow[11], Ehab L. Atallah[5], [#]Anand Ashwin Patel[1], and [#]Rory M. Shallis[12].

[1]Department of Medicine, Section of Hematology/Oncology, University of Chicago, Chicago, IL
[2]Duke University Medical Center, Durham, NC;
[3]University of Chicago Pritzker School of Medicine, Chicago, IL
[4]UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA
[5]Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
[6]Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL
[7]Duke University Cancer Institute, Durham, NC
[8]Department of Biostatistics, Yale School of Public Health, New Haven, CT
[9]Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL
[10]Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
[11]Mayo Clinic, Rochester, MN
[12]Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine - Yale Cancer Center, New Haven, CT
Senior authorship shared by A.A.P and R.M.S.

Corresponding author: Rory Shallis, Section of Medical Oncology and Hematology, Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, PO Box 208028, New Haven, CT 06520-8028; email: rory.shallis@yale.edu.

Data-sharing statement: All data reported within the manuscript and further may be available upon reasonable request to the corresponding author.

Authorship Contributions
S.J.Y. designed the study, wrote the manuscript, and aided in data collection,; W.C. performed analyses and assisted in manuscript writing; J.J.W., A.S., E.G., G.S.M., T.B., A.I., C.L., E.S.W., Y.A., M.R.L., E.L.A., and A.S. collected data and edited the manuscript; A.A.P and R.M.S designed the study, assisted in data collection, and assisted in manuscript writing.

Conflict of Interest/Disclosures
G.S.M. serves on Advisory Board for BeiGene, Gilead Sciences/Kite, Pfizer, BMS, Autolus, and Syndax, receives research funding from LOXO/Lilly, Zentalis, Schrodinger, and Merck, and serves on speakers bureau for Amgen and Rigel, and Stemline. T.B is on advisory board for Pfizer, Takeda, and Morphosys. E.L.A has received honoraria from Novartis Pharmaceuticals. C.L. serves on the advisory board for Autolus and ADC Therapeutics. Y.A. serves on scientific advisory

boards or consults for: Astellas, Bristol Myers Squibb, Daiichi Sankyo, Geron, KiTE, Pfizer, Rigel, and Servier and receives institutional trial support from AbbVie, ALX Oncology, Biomea, Biosight, Curis, and Novartis. A.A.P reports research funding (to institution) from Pfizer, Sumitomo, Incyte, Servier; honoraria from Jazz and AbbVie. R.M.S. has served in a consulting/advisory role and/or received honoraria from Bristol Myers Squibb, Geron, Gilead Sciences Inc, Kura Oncology, Rigel, Servier, Syndax Pharmaceuticals and TScan Therapeutics and has participated in a Steering Committee for Servier. The remaining authors declare no competing financial interests.

Acknowledgements
We thank Dr. Richard Larson of The University of Chicago for providing senior editorial review of our manuscript.

Abstract

A diagnosis of acute myeloid leukemia (AML) has been considered an oncologic emergency. However, the prevailing wisdom to quickly administer AML-directed therapy is often in conflict with the time needed to complete the evaluation of actionable AML disease biology. Previous studies in intensively treated patients reported that time from date of diagnosis to treatment start date (TDT) did not impact survival outcomes. We conducted a US-based, multi-center, retrospective cohort study assessing the impact of TDT on overall survival (OS) in patients with newly diagnosed AML treated with hypomethylating agents (HMA) + venetoclax at 8 participating academic centers. 488 patients were included with a median age of 76 years. Patients had favorable (47.6%), intermediate (22.8%), and adverse (29.6%) risk disease by the 2024 European LeukemiaNet (ELN) 2024 less-intensive risk classification. Median TDT for the cohort was 9 days (IQR: 5-17). Those with TDT <14 days (median OS: 8.2 months; 95%CI: 6.8 – 9.9) versus ≥14 days (median OS: 11.3 months; 95%CI: 9.5 – 15.4) had worse OS (p=0.007). TDT ≥ 14 days was associated with improved OS in multivariable analysis (HR: 0.73, 95% CI: 0.54 to 0.97; p=0.033) adjusting for age, performance status, use of cytoreductive therapy, WBC at presentation, ELN 2024 less-intensive risk classification, and presence of *FLT3*-ITD*, TP53,* and *IDH1/2* mutations. These results suggest that stable patients with newly diagnosed AML eventually treated with HMA + venetoclax may await appraisal of disease biology and medical optimization before initiating induction therapy.

Introduction

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that has been considered by many oncologists to be an oncologic emergency often leading to immediate hospital admission for expeditious evaluation and treatment. However, the prevailing wisdom to quickly administer AML-directed therapy is commonly in conflict with the time needed to complete the evaluation of actionable AML disease biology. The past two decades have seen substantial progress in the availability and use of molecular testing in the form of polymerase chain reaction (PCR) and next generation sequencing (NGS) to better inform AML subtype, the utility in using one of the growing armamentarium of targeted agents including IDH and FLT3 inhibitors,[1-4] assessing prognosis, and defining the best consolidative strategy that may include allogeneic hematopoietic stem cell transplantation (alloHCT). These events can lengthen the time from diagnosis to treatment initiation as most commercial and academic center NGS panels average up to two weeks turn-around time depending on the number of genes assessed and the laboratory performing the test. Some centers have validated and perform "rapid" NGS panels that evaluate a limited number of genes with more immediate treatment implications and can shorten the turn-around time, which can still be up to one week.[5] The time currently required to ascertain PCR/NGS data for newly diagnosed AML is also used in parallel for pre-treatment activities such as baseline echocardiogram evaluation, central venous catheter placement, the arrangement of sub-specialist evaluation(s), optimization via nutritionists and physical therapists, and evaluation for clinical trials.[6]

A few studies over the past decade have evaluated whether time from diagnosis to treatment (TDT) impacts outcomes in patients with newly diagnosed AML.[7-9] Three key studies by Sekeres *et al*, Bertoli *et al*, and R□llig *et al* evaluated large cohorts of United States (US), French, and German patients, respectively, treated with intensive induction regimens. All three studies found no difference in survival with longer TDT in older adults (age ≥60 years), although there was discordance when evaluating younger, US patients who had inferior OS when treatment was initiated beyond 5 days from diagnosis.[7] These results have recently been challenged by large, population-based studies of Swedish and US intensively-treated patients who were shown to have worse OS with longer TDT.[10, 11] However, the impact of TDT on outcomes amongst patients with AML receiving less-intensive regimens, including *de facto* standard of care hypomethylating agent (HMA) + venetoclax, is largely unknown.[12-14] A recent retrospective German study evaluated a combined cohort of patients treated with HMA/low-dose cytarabine + venetoclax for newly diagnosed AML as ascertained from registry (n=138) and electronic health record data (n=717) and found no difference in overall survival (OS) when using a dichotomous TDT cutoff of 10 days (i.e., <10 days versus TDT ≥10 days).[15] To date, no study has assessed the impact of TDT exclusively in HMA + venetoclax treated patients. This gap in knowledge is particularly relevant considering that most patients will receive less-intensive frontline therapy, these regimens are being investigated against intensive therapy for many subgroups, the proportion of patients having molecular testing will further improve, and, lastly, AML diagnosis and sub-classification will increasingly rely upon biological data.[4] We conducted a US-based, multi-center, retrospective cohort study from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND) assessing the impact of TDT on outcomes in patients with newly diagnosed AML treated with HMA + venetoclax. We hypothesized that TDT

would not impact OS, even after accounting for relevant clinicopathologic covariates, due to the importance of a thorough biologic evaluation and the predictive value of mutational and cytogenetic profiling preceding treatment initiation.

Methods

Study Design, Setting, and Population

This retrospective cohort study was comprised of adult patients with newly diagnosed AML treated with HMA + venetoclax, either on trial or off-trial, identified by chart review at 8 participating US academic centers. Data collection ended May of 2024. AML was defined as per 4th edition WHO classification of myeloid neoplasms and acute leukemias.[16] Patients with AML progressed from MDS or MPN with prior exposure to HMA therapy were included in the analysis and prior HMA exposure was collected as a covariate. Patient demographics were collected including age at diagnosis, sex and self-reported race/ethnicity.

Variables

TDT was defined as number of days between date of diagnosis and date of initiation of HMA + venetoclax. The dose, duration, number of cycles to first and best response, number of cycles in total, treatment setting (inpatient or outpatient) of venetoclax, and receipt of alloHCT in first remission was collected. Laboratory data at presentation including complete blood count and complete metabolic panel data inclusive of transaminases, baseline uric acid, lactate dehydrogenase and presence of tumor lysis syndrome (TLS) evaluation were collected. Cytogenetic profiling was done by fluorescence *in situ* hybridization (FISH) and conventional chromosome analysis/full karyotyping, while molecular analyses were completed by each institution's myeloid gene panel via NGS and PCR. A prognostic risk score was assigned using the 2024 European LeukemiaNet (ELN) less-intensive risk classification.[17] Key patient-specific variables of fitness for anti-leukemic therapy, hematopoietic stem cell transplant comorbidity index (HCT-CI) score and ECOG Performance Status (ECOG PS), were collected in order to control for the impact of patient fitness on TDT.[18] HCT-CI score $\geq$3 and ECOG PS $\geq$3 defined high comorbidity burden and poor performance status, respectively.[19, 20] To control for severity of presentation biasing early TDT toward worse OS, white blood cell (WBC) count at diagnosis was categorized as $\geq$25,000 or <25,000 and data on the use cytoreductive therapy inclusive of receipt of hydroxyurea and use of leukocytapheresis were collected. Cause of death was documented for all patients.

Outcomes

Response to HMA + venetoclax was assessed using the 2022 ELN AML response criteria.[6] Measurable residual disease (MRD) status at time of remission was defined by multiparameter flow cytometric analysis as per each institution's standard. OS was defined as days from initiation with HMA + venetoclax to date of death. Early death, defined as death within 30 or 60 days, was assessed from date of treatment initiation.

Statistical Methods

The primary objective was to evaluate the association between TDT and OS. We explored the hazards ratio of OS against restricted cubic splines of TDT, and decided to use TDT ≥ 14 in multivariable Cox model given this timepoint's alignment with most commercial and academic center NGS panels average turn-around times. Description of continuous baseline variables of the entire cohort were summarized using medians and interquartile ranges. Methods for time-to-event data, such as the Kaplan-Meier method and Cox proportional hazards model, were applied to OS. Multivariable Cox model was conducted controlling for the following: HMA used, ECOG PS, age at diagnosis, AML type, WBC at diagnosis ≥ 25,000, receipt of cytoreduction, alloHCT in CR1, ELN 2024 less-intensive risk classification[17]; the backward elimination method (based on p-values between nested models) was applied to mutations detected by NGS other than *FLT3-ITD* which we mandated be included given the proliferative nature of that AML subtype. *FLT3*-ITD, *TP53*, and *IDH1/2* were included in the final model while RAS pathway and *NPM1* mutations were not selected by the backward elimination method. All analyses were performed using R (The R Foundation for Statistical Computing).

Each institution received approval from the institutional review board to conduct this retrospective project. All investigators ensured the planning, conduct, and reporting of this human research was in accordance with the Declaration of Helsinki. The manuscript was written in accordance with The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines for cohort studies.[21]

Results

Description of Patients

488 patients were included in the analysis. Median age was 76 years (interquartile range (IQR): 70-80), 57% were male, 78.5% were White/Caucasian (Table 1). An ECOG PS ≤2 and HCT-CI score of ≤2 was assigned to 91.2% and 52.8% of patients, respectively. Patients had favorable (47.6%), intermediate (22.8%), and adverse (29.6%) risk disease by ELN 2024 less-intensive risk, respectively. The most common mutations identified were *TP53* (27.5%), *IDH1/2* (19.3%), *NPM1* (16.4%), *DNMT3A* (16.8%), *ASXL1* (15.4%), and *FLT3*-ITD (13.7%). AML progressed from MDS or MPN occurred in 30% of patients, 21% of whom had prior HMA exposure prior to transformation to sAML.

Description of Treatment

Twenty-seven percent of patients received cytoreduction with either hydroxyurea (24%) or leukapheresis (3%) prior to initiation of HMA + venetoclax (Table 2). Azacitidine + venetoclax was the most common regimen utilized (59.7%). Median number of cycles of HMA + venetoclax received was 3 (IQR: 1-6) and 7.4% of the cohort proceeded to alloHCT in first remission.

Responses and survival of the cohort

Median follow-up for the entire cohort was 7.3 months. MRD-negative CR, MRD-positive CR, and CRi was achieved in 21.5%, 10.5%, and 16.4% of patients while recieving HMA + venetoclax. There were 114 patients (23.4%) who relapsed after date of first remission with a median of

7.75 months to relapse from first remission. Median OS for the cohort was 9.5 months (95% CI: 8.2 – 10.5). Early death, occurred in 6.0% and 15.2% of patients at 30 and 60 days, respectively.

Time from Diagnosis to Treatment

Median TDT for the cohort was 9 days (IQR: 5-17). Differences in TDT by baseline patient characteristics and treatments are shown in Tables 1 and 2, respectively. TDT did not differ by treatment regimen, HCT-CI score, receipt of alloHCT in CR1, response to induction therapy. However, TDT did differ by *IDH1/2* status, ECOG PS, WBC at presentation, requirement of cytoreduction, and ELN 2024 less-intensive risk category. Patients with *IDH1/2*-mutated disease compared to those with *IDH1/2* wild-type disease (7.0 (4.0 – 14.3) vs. 9.0 (5.0 – 18.0); p=0.031), ECOG of 3-4 compared to those of ECOG of 0 (8.5 (4.0 – 13.0) vs. 11.0 (6.5 –23.0); p=0.022), WBC >25,000 compared to those with WBC <25,000 (6 (4 – 11) vs. 10 (5 – 19); p<0.0001), and those who received cytoreduction, compared to those who did not (7 (4 – 11) vs. 10 (5 – 19); p=0.0004), all had shorter TDT. Longer TDT was associated with improved OS in univariate analysis (HR: 0.99, 95% CI: 0.98 to 0.999; p= 0.026), and TDT ≥14 days was associated with improved OS in multivariable analysis (HR: 0.73, 95% CI: 0.54 to 0.97; p=0.033) adjusting for age, ECOG PS, AML type (*de novo* vs progressed from MDS or MPN or therapy-related), use of cytoreductive therapy, WBC at presentation, prior HMA exposure, ELN 2024 less-intensive risk classification, and mutational status of *FLT3*-ITD*, TP53,* and *IDH1/2.* When comparing TDT <14 days (median OS: 8.2 months; 95% CI: 6.8 – 9.9) and ≥14 days (median OS: 11.3 months; 95% CI: 9.5 – 15.4) a difference in OS was noted (p=0.007, log-rank test). In the final multivariable Cox model (Table 3), TDT ≥14 days (p=0.033), ECOG PS 3-4 (p=0.002), AML progressed from MDS or MPN (p=0.008) or therapy-related (p=0.013), *IDH1/2* (p=0.025), *TP53* (p=0.026), and receipt of alloHCT in CR1 (p=0.0003) were significant after having adjusted for other factors. Simililarly, in the multivariable logistic regression model for 60-day mortality (Table 4) those with TDT ≥14 days had lower 60-day mortality rates compared to <14 days (OR: 0.45; 95% CI: 0.21-0.93; p=0.04). No variables were statistically significant in predicting 30-day mortality.

Discussion

In this US-based, multi-center, retrospective cohort study in patients with newly diagnosed AML treated with HMA + venetoclax we found longer TDT did not associate with worsening in patient outcomes, even when controlling for key patient- and disease-related variables known to impact survival in newly diagnosed patients with AML treated with less-intensive regimens. We speculate the association of marginal improvement in OS among those with longer TDT is due to two factors. First, more unfit patients (defined by ECOG PS, HCT-CI score) were treated earlier, potentially due to being excluded at diagnosis for clinical trials and thus providers initiating the de facto standard of care regimen. Additionally, patients who had a longer TDT may have benefited from thorough treatment planning and medical optimization, including comorbidities, infectious complications, dietician intervention, and physical therapy evaluation and optimization, prior to starting treatment. Notably, even in patients requiring cytoreduction there was no detriment noted with longer TDT in our multivariable analysis for OS, suggesting that treating physicians can allow for medical optimization and molecular testing to return before administering HMA+venetoclax in most clinically stable patients.

Our findings add to the body of literature on TDT in newly diagnosed AML as the first to describe the impact of TDT in the ever-expanding population of patients treated with frontline HMA + venetoclax in the US. Baden *et al* described TDT amongst German patients treated with venetoclax-based regimens inclusive of HMA + venetoclax and low-dose cytarabine + venetoclax (with an unknown distribution between the regimens) using registry (n=138) and electronic medical record (EMR) (n=718) data. This analysis found that treatment before or after 10 days from diagnosis had no impact on survival or 30- or 60-day mortality when controlling for comorbidity status, age, and disease severity as assessed via WBC count at presentation.[15] Wolach *et al* recently found no differences in OS when assessing TDT at cut offs of 7 and 14 days in a prospective, real-world cohort of patients with AML treated with venetoclax-containing regimens.[22] The bulk of literature, namely derived from three large European cohorts and two large US cohorts, describing the impact of TDT on outcomes, has focused on intensively treated patients and has offered divergent findings. Sekeres *et al* evaluated 1,317 US patients diagnosed at MD Anderson Cancer Center and the Cleveland Clinic and found that patients age ≤60 years, but not older adults, had worse overall survival when TDT was >5 days.[7] Similar findings were shown from real-world academic and community practice data in the National Cancer Database from 55,985 incident cases of AML diagnosed and treated intensively during 2004-2018 where patients age ≤60 years, but not age >60 years had worse OS at a TDT of 5-9 or ≥9 days when compared with 1-4 days.[10] Limitations of these data include the lack of an accounting for cytogenetic or molecular data, receipt of cytoreduction, patient frailty as measured by accepted surrogates like performance status, and a small effect size with relatively higher 5-year number needed to treat. Analyses of European cohorts such as those from France[9], Germany[8], and Sweden[11] all show no difference on outcomes by TDT, regardless of age group, in multivariable analyses when comparing TDT categorically by ≤5 days or ≤1 day vs a number of other strata (e.g., 0-5, 6-10, >15 days or 2-3, 4-6, >6 days, respectively). [8, 9, 11] Differences in findings from European and US-based cohorts of intensively treated patients may potentially be explained by differences in treatment regimens, specifically that European groups often employ double induction strategies and higher doses of cytarabine.

A demonstration of lack of detrimental effect of increasing TDT with outcomes amongst patients who initiate treatment with HMA + venetoclax has immediate clinical relevance. Our findings suggest that AML providers can defer immediate induction for most, stable patients and await a comprehensive patient and disease evaluation, including NGS results, with most attention to the ascertainment of disease biology that can strongly influence induction regimen preference and clinical trial eligibility. This finding is in line with the recommendation from the recent expert panel from the ELN providing recommendations on fitness assessment in AML. Specifically, there was high (96%) level of agreement for the statement, "Because the time to treatment start does not seem to affect short- and long-term outcomes, comprehensive fitness and biological assessment should be conducted before starting therapy."[18] Our finding is particularly relevant for an older adult population that is more likely to present with increased comorbidity burden, higher ECOG PS, higher risk disease biology, and are less likely to be offered potentially curative therapies such as alloHCT in comparison to their younger counterparts.[23-27] This population is highly likely to be treated with HMA + venetoclax, a regimen that may soon extend as a standard for younger patients with adverse disease risk, depending

on the results of ongoing randomized clinical trials (NCT04801797, NCT03573024, NCT05554393, NCT05554406).[28] The absence of longer TDT having no adverse impact on outcomes as shown in our cohort provides potential opportunities to optimize care for this vulnerable patient population and reduce healthcare utilization with unnecessary hospital admission and pre-mature, sub-optimal treatment selection. This afforded time allows for the addressing of AML-attributable complications at presentation, either with cytoreduction, anti-microbial therapy or other supportive measures, and the possibility of abrogating initially assigned barriers to intensive induction. Furthermore, providers may be provided an appropriate window to perform a comprehensive assessment of fitness and frailty. Multiple studies have shown the feasibility and prognostic significance of fitness and frailty evaluation via a comprehensive geriatric assessment (CGA) in older adults with AML receiving both intensive induction and less-intensive regimens.[29-32] Yet, incorporation of CGA into standard clinical practice is lacking due in part to concerns of lack of time to perform the assessment.[33] "Pre-habilitation" optimization programs guided by a CGA have shown to improve outcomes in patient's undergoing alloHCT and CAR-T therapy and could potentially be explored in these patients.[34-36] Future work to identify disease biology defining "clinically stable AML", a subset behaving more like high-risk MDS, and thus the true beneficiaries of prolonged TDT and prehabilitation, is warranted.[37, 38]

Our study has several limitations, most notably the retrospective design limiting our ability to collect several relevant data points. First, we are unable to report on those who died before receiving HMA+venetoclax. However, in the BEAT AML master trial, a US-based, multicenter, precision medicine trial in AML that aimed to prospectively assess the feasibility of assigning treatment based on cytogenetic and molecular results for older patients with AML in ≤7 days, only 6/395 (1.5%) of patients enrolled on protocol died prior to beginning treatment.[39] Thus, we feel capturing similar patients within our cohort and the associated Immortal Time Bias would not have significantly altered our results. Due to the retrospective nature of this work we also were unable to systematically collect reasons for longer TDT, the degree to which NGS results informed treatment decision making given the entire cohort received HMA+venetoclax, and the degree of optimization of patient fitness that occurred during the time from diagnosis to treatment. We also did not systematically collect severity and duration of neutropenia, time from diagnosis to receiving the NGS/cytogenetic data and its association with TDT and outcome. Given the lack of data on neutropenia duration and severity in our analysis, caution ought to be utilized by clinicians applying our findings to those neutropenic at diagnosis. Finally, the survival in our cohort was inferior to those reported from VIALE-A[12] and the UK NHS real-world cohort (13.6 (95% CI, 11.7-15.1)[40], but similar to previous single-center[41, 42] and community-based[43, 44] studies which reported a median OS of 8 to 11 months. The lower OS observed in comparison to VIALE-A and UK NHS cohort may be, in part, explained by the higher rate of patients with AML progressed from MDS or MPN and therapy-related AML included in this study (46%) compared to that of the VIALE-A population (25%) and UK NHS (31%). Amongst those with AML progressed from MPN or MDS, 21% (31) patients had prior HMA exposure in our cohort compared to 8% in UK NHS. We also included those with ECOG PS >2 (8.8% of our cohort), a subgroup who did particularly poorly and was excluded from VIALE-A.

In conclusion, utilizing a large, multi-centre, retrospective, US-based cohort we demonstrate that a longer TDT was not associated with worse survival for patients with newly diagnosed AML treated with HMA + venetoclax even when controlling for severity of presentation and patient fitness. Our findings suggest that in clinically stable patients, time is available to conduct a thorough assessment inclusive of diagnostic/prognostic/predictive disease biology, patient fitness, AML sub-specialist evaluation, and clinical trial eligibility prior to therapy initiation.

References

1. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation. N Engl J Med. 2017;377(5):454-464.
2. Montesinos P, Recher C, Vives S, et al. Ivosidenib and Azacitidine in IDH1-Mutated Acute Myeloid Leukemia. N Engl J Med. 2022;386(16):1519-1531.
3. Erba HP, Montesinos P, Kim H-J, et al. Quizartinib plus chemotherapy in newly diagnosed patients with FLT3-internal-tandem-duplication-positive acute myeloid leukaemia (QuANTUM-First): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2023;401(10388):1571-1583.
4. Grinblatt DL, Roboz GJ, Pollyea DA, et al. Treatment Patterns and Outcomes of Patients with Acute Myeloid Leukemia (AML) from 2013 to 2022: A Connect ® Myeloid Registry Study. Blood. 2023;142(Supplement 1):593.
5. Duncavage EJ, Bagg A, Hasserjian RP, et al. Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia. Blood. 2022;140(21):2228-2247.
6. Döhner H, Wei AH, Appelbaum FR, et al. Diagnosis and Management of AML in Adults: 2022 ELN Recommendations from an International Expert Panel. Blood. 2022;140(12):1345-1377.
7. Sekeres MA, Elson P, Kalaycio ME, et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients. Blood. 2009;113(1):28-36.
8. Röllig C, Kramer M, Schliemann C, et al. Does time from diagnosis to treatment affect the prognosis of patients with newly diagnosed acute myeloid leukemia? Blood. 2020;136(7):823-830.
9. Bertoli S, Berard E, Huguet F, et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. Blood. 2013;121(14):2618-2626.
10. Alsouqi A, Rothenberger SD, Boyiadzis M, Lontos K. Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55□985 patients from the National Cancer Database. Br J Haematol. 2022;199(2):256-259.
11. Juliusson G, Hagberg O, Lazarevic VL, Lehmann S, Höglund M. Impact of treatment delay in acute myeloid leukemia revisited. Blood Adv. 2021;5(3):787-790.
12. DiNardo CD, Jonas BA, Pullarkat V, et al. Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. N Engl J Med. 2020;383(7):617-629.
13. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133(1):7-17.
14. Male HJ, Lin TL. The approach of HMA plus VEN with or without BMT for all patients with AML. Hematology Am Soc Hematol Educ Program. 2023;2023(1):186-191.
15. Baden D, Zukunft S, Hernandez G, et al. Time from diagnosis to treatment has no impact on survival in newly diagnosed acute myeloid leukemia treated with venetoclax-based regimens. Haematologica. 2024;109(8):2469-2477.

16. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-2405.
17. Döhner H, DiNardo CD, Wei AH, et al. Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations. Blood. 2024;144(21):2169-2173.
18. Venditti A, Palmieri R, Maurillo L, et al. Fitness assessment in acute myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood Adv. 2025;9(9):2207-2220.
19. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106(5):1090-1098.
20. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8):2912-2919.
21. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344-349.
22. Wolach O, Levi I, Nachmias B, et al. Trial eligibility, treatment patterns, and outcome for venetoclax-based therapy in AML: a prospective cohort study. Blood Adv. 2025;9(7):1544-1554.
23. Rosko AE, Cordoba R, Abel G, Artz A, Loh KP, Klepin HD. Advances in Management for Older Adults With Hematologic Malignancies. J Clin Oncol. 2021;39(19):2102-2114.
24. Mishra A, Preussler JM, Bhatt VR, et al. Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. Transplant Cell Ther. 2021;27(7):617.e1-617.e7.
25. Lai C, Bhansali RS, Kuo EJ, Mannis G, Lin RJ. Older Adults With Newly Diagnosed AML: Hot Topics for the Practicing Clinician. Am Soc Clin Oncol Educ Book. 2023;43:e390018.
26. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107(9):3481-3485.
27. Klepin HD. Geriatric perspective: how to assess fitness for chemotherapy in acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2014;2014(1):8-13.
28. Lu J, Xue S, Wang Y, et al. Venetoclax and Decitabine vs Intensive Chemotherapy as Induction for Young Patients with Newly Diagnosed AML. Blood. 2025;145(22):2645-2655.
29. Bhatt VR, Uy GL, Klepin HD. Determining treatment tolerance and fitness for intensive chemotherapy in older adults with AML: a call to action. Blood. 2024;143(6):483-487.
30. Klepin HD, Ritchie E, Major-Elechi B, et al. Geriatric assessment among older adults receiving intensive therapy for acute myeloid leukemia: Report of CALGB 361006 (Alliance). J Geriatr Oncol. 2020;11(1):107-113.

31. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013;121(21):4287-4294.
32. Min G-J, Cho B-S, Park S-S, et al. Geriatric assessment predicts nonfatal toxicities and survival for intensively treated older adults with AML. Blood. 2022;139(11):1646-1658.
33. Dale W, Klepin HD, Williams GR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy: ASCO Guideline Update. J Clin Oncol. 2023;41(26):4293-4312.
34. Derman BA, Kordas K, Ridgeway J, et al. Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults. Blood Adv. 2019;3(22):3488-3498.
35. Yates SJ, Cursio JF, Artz AS, et al. Optimization of Older Adults by a Geriatric Assessment-Guided Multidisciplinary Clinic Prior to CAR T-Cell Therapy. Blood Adv. 2024;8(14):3785-3797.
36. Lew MV, Ren Y, Lowder YP, et al. Geriatric Assessment Reveals Actionable Impairments in Hematopoietic Stem Cell Transplantation Candidates Age 18 to 80 Years. Transplant Cell Ther. 2022;28(8):498.e1-498.e9.
37. Gurnari C, Robin M, Adès L, et al. Clinical-genomic profiling of MDS to inform allo-HCT: recommendations from an international panel on behalf of the EBMT. Blood. 2025;145(18):1987-2001.
38. Schroeder JC, Mix L, Faustmann P, et al. Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome. Bone Marrow Transplant. 2024;59(9):1332-1334.
39. Burd A, Levine RL, Ruppert AS, et al. Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial. Nat Med. 2020;26(12):1852-1858.
40. Othman J, Lam HPJ, Leong S, et al. Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS. Blood Neoplasia. 2024;1(3):100017.
41. Winters AC, Gutman JA, Purev E, et al. Real-world experience of venetoclax with azacitidine for untreated patients with acute myeloid leukemia. Blood Adv. 2019;3(20):2911-2919.
42. Morsia E, McCullough K, Joshi M, et al. Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients. Am J Hematol. 2020;95(12):1511-1521.
43. Gershon A, Ma E, Xu T, et al. Early Real-World First-Line Treatment With Venetoclax Plus HMAs Versus HMA Monotherapy Among Patients With AML in a Predominately US Community Setting. Clin Lymphoma Myeloma Leuk. 2023;23(5):e222-e231.
44. Vachhani P, Flahavan EM, Xu T, et al. Venetoclax and Hypomethylating Agents as First-line Treatment in Newly Diagnosed Patients with AML in a Predominately Community Setting in the US. Oncologist. 2022;27(11):907-918.

Table 1: Characteristics of 488 patients with newly diagnosed acute myeloid leukemia with comparison of time from diagnosis to treatment according to these characteristics

Characteristic	**n (%), total 488**	**TDT (days) [median (IQR)]**	**P-value ***
Age at diagnosis, median (IQR)	76 (70 – 80)		
< 75, n	209	8 (5 – 15)	Ref
≥ 75, n	279	10 (5 – 19)	0.076
Sex, n (%)			
Male	278/488 (57.0%)	9 (5 – 17)	Ref
Female	210/488 (43.0%)	9 (5 – 17)	0.789
ECOG Performance Status, n (%),			
0	51/431 (11.8%)	11.0 (6.5 – 23.0)	Ref
1	223/431 (51.7%)	10.0 (5.0 – 19.0)	0.130
2	119/431 (27.6%)	8.0 (5.0 – 15.0)	0.077
3-4	38/431 (8.8%)	8.5 (4.0 – 13.0)	0.022
HCT-CI score			
0-2	159/301 (52.8%)	9.0 (4.0 – 16.0)	Ref
≥3	142/301 (47.2%)	7.0 (4.0 – 13.8)	0.259
Received cytoreduction (vs not)	135/478 (28.2%)	6 (4 – 11) vs 11 (5 – 19)	**< 0.0001**
Cytoreduction: hydroxyurea alone, n (%)	89 vs 377		
Received hydroxyurea	89/466 (19.1%)	7 (4 – 12)	Ref
No cytoreduction	377/466 (80.9%)	10 (5 -- 19)	<0.001
Cytoreduction: leukapheresis and hydroxyurea, n (%)			
Received leukapheresis and hydroxyurea	101/377	7 (4 – 11)	Ref
No cytoreduction	266/377	10 (5 – 19)	<0.001
WBC at diagnosis			
WBC at diagnosis, ≥ 25K	118/483 (24.4%)	6 (4 – 11)	Ref
WBC at diagnosis < 25K	365/483 (75.6%)	10 (5 - 19)	< 0.0001
ELN 2022 risk category, n (%)			
Favorable	46/467 (9.9%)	6.5 (4.0 – 14.0)	Ref
Intermediate	91/467 (19.5%)	9.0 (4.0 – 17.0)	0.375
Adverse	330/467 (70.7%)	9.0 (5.0 – 17.0)	0.171
ELN 2024 less-intensive risk, n (%)			
Favorable	215/452 (47.6%)	11.0 (5.0 – 19.5)	Ref
Intermediate	103/452 (22.8%)	7.0 (4.0 – 13.0)	0.003
Adverse	134/452 (29.6%)	8.0 (4.0 – 14.0)	0.004
Molecular Testing, n (%) (Ref: Wt)			
FLT3-ITD present	67/461 (14.5%)	7.0 (3.5 – 11.5) vs 9.0 (5.0 – 17.0)	0.052
FLT3-ITD or *FLT3*-TKD present	78/461 (16.9%)	7.0 (3.3 – 12.8) vs	0.063

		9.0 (5.0 – 17.0)	
IDH1/2 mutated	92/462 (19.9%)	7.0 (4.0 – 14.3) vs 9.0 (5.0 – 18.0)	0.031
TP53 mutated	134/451 (29.7%)	8 (4 – 14) vs 9 (5 – 19)	0.060
NPM1 mutated	80/447 (17.9%)	7 (4 – 14) vs 9 (5 – 17)	0.105
DNMT3A mutated	82/438 (18.7%)	8.5 (4.0 – 15.0) vs 9.0 (5.0 – 17.0)	0.625
***De novo* AML**	256/486 (52.7%)	8.0 (4.0 – 16.0)	Ref
Therapy-related AML	78/486 (16.0%)	9.5 (6.0 – 14.0)	0.228
AML progressed from MDS or MPN	146/486 (30.0%)	10.0 (4.3 – 22.8)	0.150
Prior HMA Exposure, n (%)			
Prior HMA exposure: yes	31/347 (8.9%)	13.0 (7.0 – 23.5)	Ref
Prior HMA exposure: no	316/347 (91.9%)	8.0 (5.0 – 15.3)	0.045

* Wilcoxon rank sum test for the comparison of TDT between two groups. AML, acute myeloid leukemia; DNMT3A, DNA methyltransferase 3 alpha; ELN, European LeukemiaNet; FLT-3 ITD, FMS-like tyrosine kinase 3 internal tandem duplication; FLT-3 TKD, FMS-like tyrosine kinase 3 tyrosine kinase domain; HCT-CI, hematopoietic stem cell transplant comorbidity index; HMA, hypomethylating agent; IDH, isocitrate dehydrogenase; IQR, interquartile range; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; NMP1, nucleophosmin 1; TDT, time from diagnosis to treatment; TP53, tumor protein 53; WBC, white blood cell, WT; wild type.

Table 2: Differences in time from diagnosis to treatment by treatment received, receipt of transplant, and response to frontline therapy.

Characteristic	**n (%)**	**TDT in days, median (IQR)**	**P-value**
Treatment regimen, n, (%)			
Azacitidine + venetoclax	263/440 (59.7%)	9 (5 – 17)	Ref
Decitabine + venetoclax	177/440 (40.3%)	8 (4 – 15)	0.057
Receipt of alloHCT, n, (%)			
Yes	36/486 (7.4%)	9.5 (7.0 – 15.5)	0.510
No	450/486 (92.6%)	9.0 (4.3 – 18.0)	Ref
Response to frontline therapy, n (%)			
MRD-negative CR	105/426 (24.6%)	9.0 (5.0 – 15.0)	0.460*
MRD-positive CR	51/426 (11.9%)	9.0 (6.0 – 21.5)	
CRi	80/426 (18.8%)	11.5 (4.0 – 19.0)	
MLFS	36/426	11.0 (5.0 – 17.3)	
Partial response	33/426	7.0 (4.0 – 13.0)	
Progressive disease	71/426	13.0 (6.0 – 19.0)	
Stable disease	50/426	8.0 (4.0 – 13.0)	

*Compares TDT of those MRD-negative CR, MRD-positive CR and CRi with partial response/progressive disease/stable disease. AlloHCT, allogeneic hematopoietic stem cell transplant; CR, complete remission; CRi, CR with incomplete hematologic recovery; IQR, interquartile range; MLFS, morphologic leukemia-free state; MRD, measurable residual disease; TDT, time from diagnosis to treatment.

Table 3: Multivariable analysis of time from diagnosis to treatment effect on overall survival in the entire cohort based on disease biology, hypomethylating agent used, age, and receipt of allogeneic stem cell transplant in first complete remission.

Variable in Cox Proportional Hazards Model:	Hazard Ratio (95% CI)	P-value
Time from diagnosis to treatment ≥14 days (reference: <14 days)	**0.73 (0.54 to 0.97)**	**0.033**
Treatment regimen (reference: AZA + venetoclax)		
Decitabine + venetoclax	1.17 (0.90 to 1.53)	0.246
Age at diagnosis	1.00 (0.98 to 1.01)	0.617
ECOG Performance Status (reference: 0)		
1	1.07 (0.72 to 1.60)	0.724
2	1.39 (0.91 to 2.11)	0.128
3-4	**2.23 (1.34 to 3.71)**	**0.002**
AML type (reference: *de novo*)		
Progressed from MDS or MPN	**1.46 (1.08 to 1.96)**	**0.013**
Therapy-related	**1.58 (1.09 to 2.31)**	**0.016**
WBC at diagnosis ≥ 25,000 (reference: < 25,000)	1.27 (0.77 to 2.09)	0.355
Receipt of cytoreduction (reference: No)	1.01 (0.61 to 1.67)	0.979
Mutation status (reference: Wt)		
FLT3-ITD present	1.00 (0.56 to 1.77)	0.987
IDH1/2 mutated	**0.65 (0.44 to 0.95)**	**0.025**
TP53 mutated	**1.79 (1.07to 2.98)**	**0.026**
ELN 2024 Less-Intensive Risk: (reference: Adverse)	0.99 (0.60 to 1.63)	0.955
AlloHCT in CR1 (reference: No)	**0.32 (0.17 to 0.59)**	**0.0003**

*Multivariable analysis was conducted controlling for the following: AML type, ECOG Performance Status, age, WBC at diagnosis, receipt of cytoreduction, ELN 2024 Less Intensive risk classification. AML, acute myeloid leukemia; AlloHCT, allogeneic hematopoietic stem cell transplant; AZA, azacitidine; ECOG, eastern cooperative oncology group; ELN, European LeukemiaNet; FLT-3 ITD, FMS-like tyrosine kinase 3 internal tandem duplication; HMA, hypomethylating agent; IDH, isocitrate dehydrogenase; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; TP53, tumor protein 53; WBC, white blood cell.

Table 4. Multivariable logistic regression of death within 60 days from initiation of treatment with hypomethylating agents + venetoclax

Variables in logistic regression model:	**Odds Ratio (95% CI)**	**P-value**
Time from diagnosis to treatment ≥14 days (reference: <14 days)	**0.45 (0.21 to 0.93)**	**0.039**
Treatment regimen (reference: AZA + venetoclax)		
Decitabine + venetoclax	1.02 (0.54 to 1.91)	0.938
Age at diagnosis	1.00 (0.96 to 1.04)	0.980
ECOG Performance Status (reference: 0)		
1	2.03 (0.63 to 9.13)	0.285
2	**3.84 (1.18 to 17.33)**	**0.043**
3-4	**5.75 (1.54 to 28.22)**	**0.015**
AML type (reference: *de novo*)		
Progressed from MDS or MPN	1.21 (0.60 to 2.40)	0.595
Therapy-related	1.40 (0.60 to 3.18)	0.420
WBC at diagnosis ≥ 25,000 (reference: < 25,000)	0.44 (0.14 to 1.43)	0.164
Receipt of cytoreduction (reference: No)	1.49 (0.47 to 4.37)	0.475
Mutation status (reference: Wt)		
FLT3-ITD present	1.58 (0.45 to 6.06)	0.480
IDH1/2 mutated	0.70 (0.28 to 1.61)	0.419
TP53 mutated	1.63 (0.56 to 5.57)	0.397
ELN 2024 Less-Intensive Risk: (reference: Adverse)	0.95 (0.32 to 3.26)	0.934

* Multivariable analysis was conducted controlling for the following: AML type, ECOG Performance Status, age, WBC at diagnosis, receipt of cytoreduction, ELN 2024 Less Intensive risk classification. AML, acute myeloid leukemia; AZA, azacitidine; ECOG, eastern cooperative oncology group; ELN, European LeukemiaNet; FLT-3 ITD, FMS-like tyrosine kinase 3 internal tandem duplication; HMA, hypomethylating agent; IDH, isocitrate dehydrogenase; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasm; TP53, tumor protein 53; WBC, white blood cell.

Figure Legends

Figure 1. Survival curves for 488 adults with acute myeloid leukemia treated with hypomethylating agents + venetoclax within the United States-based Consortium on Myeloid Malignancies and Neoplastic Diseases. Median overall survival for the entire cohort (A) was 9.5 months (95% CI: 8.2 – 10.5). When comparing time from diagnosis <14 days (median OS: 8.2 months; 95%CI: 6.8 – 9.9) and ≥14 days (median OS: 11.3 months; 95%CI: 9.5 – 15.4) (B) a difference in overall survival was noted (p=0.007, log-rank test).


A
1.00
0.75
0.50
0.25
0.00
Probability of Overall Survival
0
10
20
30
40
50
60
Time in months
Number at risk (number censored)
All
486 (0)
188 (59)
90 (90)
46 (109)
24 (125)
6 (138)
4 (140)
0
10
20
30
40
50
60
Time in months
B
1.00
0.75
0.50
0.25
0.00
Probability of Overall Survival
0
10
20
30
40
50
60
Time in months
Number at risk (number censored)
TDT range
< 14
321 (0)
113 (40)
53 (58)
24 (71)
11 (81)
2 (88)
0 (90)
≥ 14
165 (0)
75 (19)
37 (32)
22 (38)
13 (44)
4 (50)
4 (50)
0
10
20
30
40
50
60
Time in months